Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
WCLC 2013
15th World Conference on Lung Cancer
Access to all presentations that occurred during the 15th World Conference on Lung Cancer in Sydney, Australia.
Presentation Date(s):- October 27 - 30, 2013
- Total Presentations: 2517
-
+
P1.10 - Poster Session 1 - Chemotherapy
- Type: Poster Session
- Track: Medical Oncology
- Presentations: 57
- Coordinates: 10/28/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P1.10-004 - Exploratory Subset Analysis in African Americans from the PointBreak Study (Randomized Phase 3 Pemetrexed + Carboplatin + Bevacizumab Followed by Maintenance Pemetrexed + Bevacizumab Versus Paclitaxel + Carboplatin + Bevacizumab followed by Maintenance Bevacizumab in Patients with Stage IIIB/ IV Nonsquamous Non-Small Cell Lung Cancer)
09:30 - 09:30 | Author(s): C. Reynolds
- Abstract
Loading... -
+
P1.10-034 - Weight Gain as a Prognostic Factor on Patient Outcomes
In Advanced, Nonsquamous, Non-small Cell Lung Cancer09:30 - 09:30 | Author(s): J.D. Patel
- Abstract
Loading...
-
+
MO06 - NSCLC - Chemotherapy I
- Type: Mini Oral Abstract Session
- Track: Medical Oncology
- Presentations: 14
- Moderators:R. Perez-Soler
- Coordinates: 10/28/2013, 16:15 - 17:45, Parkside Ballroom A, Level 1
-
+
MO06.12 - Efficacy and safety of paclitaxel and carboplatin with bevacizumab for the first-line treatment of patients with nonsquamous non-small cell lung cancer (NSCLC): analyses based on age in the phase 3 PointBreak and E4599 trials
17:20 - 17:25 | Author(s): C.J. Langer
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
P2.11 - Poster Session 2 - NSCLC Novel Therapies
- Type: Poster Session
- Track: Medical Oncology
- Presentations: 46
- Coordinates: 10/29/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P2.11-006 - Review of 10 Years of ASCO Abstracts for Non-Small Cell Lung Cancer (NSCLC) and the Impact of Molecular Biomarkers (MB) in Clinical Trial Selection Criteria
09:30 - 09:30 | Author(s): R.D. Gentzler
- Abstract
Loading...
-
+
Best of Posters - IASLC Selection - Part 1
- Type: Exhibit Showcase Session
- Track:
- Presentations: 4
- Coordinates: 10/29/2013, 09:55 - 10:25, Exhibit Hall, Ground Level
-
+
P1.11-008 - A phase II study of HSP90 inhibitor AUY922 and erlotinib (E) in patients (pts) with EGFR-mutant lung cancer and acquired resistance (AR) to EGFR tyrosine kinase inhibitors (EGFR TKIs).
09:55 - 10:00 | Author(s): H.A. Yu
- Abstract
Loading...
